
Diabetes patients using Ozempic, other treatments instead of insulin have lower cancer risk, study finds
Fox News
Type 2 diabetes patients on GLP-1 treatments, including Ozempic, have a lower risk of 10 types of obesity-related cancers compared to those on insulin, according to a new study.
In the study published on Friday in medical journal JAMA Network Open, researchers examined the medical records of 1.6 million patients with type 2 diabetes who had no prior history of 13 types of obesity-related cancers including gallbladder cancer and kidney cancer.
More Related News













